Advertisement

Topics

Tenax Therapeutics, Inc. Company Profile

08:54 EST 15th December 2018 | BioPortfolio

Tenax Therapeutics, Inc. (formerly Oxygen Biotherapeutics) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical care market. The company owns the North American rights to develop and commercialize levosimendan, and the United States Food and Drug Administration (FDA) has granted Fast Track status for levosimendan for the reduction of morbidity and mortality in cardiac surgery patients at risk for developing Low Cardiac Output Syndrome (LCOS). The company initiated a Phase 3 trial with levosimendan in that indication in July 2014. For more information, visit www.tenaxthera.com.


News Articles [710 Associated News Articles listed on BioPortfolio]

Tenax Therapeutics nets $9.2mm via FOPO

Tenax Therapeutics Inc. netted $9.2mm through a follow-on offering of 5.18mm units priced at $1.93. Each unit consists of one share of Series A convertible preferred stock (conversion price is $1.93),...

Tenax Therapeutics to Present at H.C. Wainwright 20th Annual Global Investment Conference

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today ann...

Tenax Therapeutics to Present at Upcoming Investor Conferences

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today ann...

Tenax Therapeutics Activates First Clinical Research Site for Phase 2 Pulmonary Hypertension Clinical Trial

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today ann...

Tenax Therapeutics Announces Appointment of Anthony A. DiTonno as CEO

Tenax Therapeutics, Inc. (Nasdaq: TENX), a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market, today ann...

Tenax Therapeutics Announces Closing of $10 Million Underwritten Offering

Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing and commercializing products for ...

Tenax Therapeutics Announces New Clinical Study Publication Results Indicate Levosimendan Offers Renal Protective Benefits to Heart Failure Patients

Results indicate levosimendan increases glomerular filtration rate (GFR) Levosimendan may be a preferred drug for heart failure patient with imp...

Tenax Therapeutics Announces Pricing of $10 Million Underwritten Offering

Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or the “Company”), a specialty pharmaceutical company focused on identifying, developing and commercializing products for ...

PubMed Articles [470 Associated PubMed Articles listed on BioPortfolio]

A false-positive Trichomonas vaginalis result due to Trichomonas tenax presence in clinical specimens may reveal a possible Trichomonas tenax urogenital infection.

In this letter we describe a molecular investigation that showed Trichomonas tenax mis-identification as Trichomonas vaginalis by a widely used commercial multiplexed PCR kit for STI diagnosis. The in...

Effect of Tenax addition amount and desorption time on desorption behaviour for bioavailability prediction of polycyclic aromatic hydrocarbons.

In this work, Tenax consecutive extractions of polycyclic aromatic hydrocarbons (PAHs) were conducted in two spiked sediments to investigate the influence of different Tenax addition amounts and desor...

In vitro assessment of pyrethroid bioaccessibility via particle ingestion.

Due to their intensive use in agricultural and residential pest control, human exposure to residues of multiple pyrethroids frequently occurs. Pyrethroids have exceptionally high affinity for solid pa...

RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.

Effect of aging on bioaccessibility of DDTs and PCBs in marine sediment.

Hydrophobic legacy contaminants like dichlorodiphenyltrichloroethane (DDT) and polychlorinated biphenyls (PCBs) were banned almost half a century ago. While their residues still remain in many environ...

Clinical Trials [165 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1287 Associated Companies listed on BioPortfolio]

Tenax Therapeutics, Inc. 

Tenax Therapeutics, Inc., is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The Company has a wor...

Tenax Therapeutics, Inc.

Tenax Therapeutics, Inc. (formerly Oxygen Biotherapeutics) is a specialty pharmaceutical company focused on developing and commercializing a portfolio of products for the critical...

Tenax Implant Inc.

Nil

Tenax Implants

Dental Implants

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

More Information about "Tenax Therapeutics, Inc." on BioPortfolio

We have published hundreds of Tenax Therapeutics, Inc. news stories on BioPortfolio along with dozens of Tenax Therapeutics, Inc. Clinical Trials and PubMed Articles about Tenax Therapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Tenax Therapeutics, Inc. Companies in our database. You can also find out about relevant Tenax Therapeutics, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Surgical treatments
Surgery is a technology consisting of a physical intervention on tissues. All forms of surgery are considered invasive procedures; so-called "noninvasive surgery" usually refers to an excision that does not penetrate the structure being exci...


Corporate Database Quicklinks



Searches Linking to this Company Record